BR112015022103A2 - composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença - Google Patents

composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença

Info

Publication number
BR112015022103A2
BR112015022103A2 BR112015022103A BR112015022103A BR112015022103A2 BR 112015022103 A2 BR112015022103 A2 BR 112015022103A2 BR 112015022103 A BR112015022103 A BR 112015022103A BR 112015022103 A BR112015022103 A BR 112015022103A BR 112015022103 A2 BR112015022103 A2 BR 112015022103A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
disease
valsartan
rosuvastatin calcium
effects
Prior art date
Application number
BR112015022103A
Other languages
English (en)
Inventor
Tae Kim Geun
Uk Song Jeong
Kon Lee Ki
Il Kim Sun
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BR112015022103A2 publication Critical patent/BR112015022103A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica, mã‰todo para preparar uma composiã‡ãƒo farmacãšutica, uso de uma composiã‡ãƒo farmacãšutica, e, mã‰todo para prevenir ou tratar uma doenã‡a” a presente invenã§ã£o refere-se a uma composiã§ã£o farmacãªutica que inclui valsartan e rosuvastatina cã¡lcica como ingredientes ativos e um mã©todo para fabricaã§ã£o para este. a composiã§ã£o farmacãªutica que inclui valsartan e rosuvastatina cã¡lcica de acordo com a presente invenã§ã£o pode aliviar os efeitos colaterais das preparaã§ãµes simples existentes e melhora simultaneamente a submissã£o de pacientes tendo uma doenã§a cardiovascular, uma doenã§a hiperlipidãªmica e uma doenã§a complexa destas e aumenta os efeitos do tratamento e da prevenã§ã£o e, em particular, obtãªm os efeitos sinergã©ticos no tratamento de hiperlipidemia e intensifica a taxa de dissoluã§ã£o de valsartan e rosuvastatina cã¡lcica e efeitos de tratamento pela granulaã§ã£o de valsartan e misturar rosuvastatina cã¡lcica.
BR112015022103A 2013-03-12 2014-03-11 composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença BR112015022103A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130026146 2013-03-12
PCT/KR2014/002008 WO2014142521A1 (ko) 2013-03-12 2014-03-11 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법

Publications (1)

Publication Number Publication Date
BR112015022103A2 true BR112015022103A2 (pt) 2017-07-18

Family

ID=51537085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022103A BR112015022103A2 (pt) 2013-03-12 2014-03-11 composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença

Country Status (11)

Country Link
US (1) US20160045497A1 (pt)
EP (1) EP2977048A4 (pt)
JP (1) JP2016514125A (pt)
KR (2) KR20140111982A (pt)
CN (1) CN105163734A (pt)
AU (1) AU2014230304B2 (pt)
BR (1) BR112015022103A2 (pt)
CA (1) CA2903961A1 (pt)
MX (1) MX2015012666A (pt)
RU (1) RU2663460C2 (pt)
WO (1) WO2014142521A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160095826A (ko) * 2015-02-04 2016-08-12 제이더블유중외제약 주식회사 피타바스타틴 또는 이의 약학적으로 허용 가능한 염 및 발사르탄 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP3320903B1 (en) * 2015-07-08 2021-05-19 HK inno.N Corporation Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
JP5377317B2 (ja) * 2006-10-30 2013-12-25 ハナル バイオファーマ カンパニー リミテッド 放出性が制御されたアンジオテンシン−ＩＩ−受容体遮断剤とＨＭＧ−ＣｏＡ還元酵素阻害剤の複合組成物
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
RU2450823C2 (ru) * 2009-10-26 2012-05-20 Общество С Ограниченной Ответственностью "Исследовательский Центр "Комкон" Средство для лечения связанных со стрессовыми условиями заболеваний и расстройств у человека и животных, а также способ лечения и/или профилактики с использованием этого средства
UY33772A (es) * 2010-12-09 2012-07-31 Lg Life Sciences Ltd Composición farmacéutica que comprende clorhidrato de lercanidipina y valsartán como componentes activos y a un método para la preparacion de la misma.

Also Published As

Publication number Publication date
CN105163734A (zh) 2015-12-16
AU2014230304A8 (en) 2015-10-15
JP2016514125A (ja) 2016-05-19
RU2015143218A (ru) 2017-04-17
MX2015012666A (es) 2016-02-16
EP2977048A4 (en) 2017-04-26
CA2903961A1 (en) 2014-09-18
EP2977048A1 (en) 2016-01-27
AU2014230304A1 (en) 2015-10-01
KR20140111982A (ko) 2014-09-22
KR20190108090A (ko) 2019-09-23
AU2014230304B2 (en) 2018-07-05
RU2663460C2 (ru) 2018-08-06
WO2014142521A1 (ko) 2014-09-18
US20160045497A1 (en) 2016-02-18
KR102306005B1 (ko) 2021-09-28

Similar Documents

Publication Publication Date Title
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
PH12015502230B1 (en) Novel viral replication inhibitors
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
HRP20240098T1 (hr) Kombinacije fiksnih doza koje sadrže etc1002 i jedan ili više statina za liječenje ili smanjivanje kardiovaskularnih rizika
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112018010052A2 (pt) peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
EA201992382A3 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112015022103A2 (pt) composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]